Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial
<p>Abstract</p> <p>Gastrointestinal stromal tumors (GIST) are mesenchymal tumors that in the past were classified as leiomyosarcomas or leiomyomas not responding to standard sarcoma chemotherapy. In several phase I and II trials the efficacy and safety of imatinib was shown before...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-05-01
|
| Series: | European Journal of Medical Research |
| Online Access: | http://www.eurjmedres.com/content/16/5/206 |